Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed

The Journal of Clinical Investigation
Irwin D BernsteinW Raskind


Monoclonal antibody L4F3 reacts with most acute myeloid leukemia (AML) cells and virtually all normal granulocyte/monocyte colony-forming cells (CFU-GM). Our objective was to determine whether lysis of AML cells with L4F3 and complement allowed expression of normal myeloid progenitors. The five glucose-6-phosphate dehydrogenase (G6PD) heterozygous patients with AML studied manifested only a single G6PD type in blast cells and in most or all granulocyte colony-forming cells, indicating that the leukemias developed clonally. The cells remaining after L4F3 treatment from two of the patients gave rise to granulocytic colonies that expressed the G6PD type not seen in the leukemic clone, indicating that they were derived from normal progenitors (CFU-GM). L4F3-treated cells from these two patients cultured over an irradiated adherent cell layer from normal long-term marrow cultures also gave rise to CFU-GM, which were shown by G6PD analysis to be predominantly nonleukemic. In the other three patients, the progenitor cells remaining after L4F3 treatment were derived mainly from the leukemic clone. The data suggest that in vitro cytolytic treatment with L4F3 of cells from certain patients with AML can enable normal, presumably highly im...Continue Reading


Dec 1, 1994·Cancer Immunology, Immunotherapy : CII·K J McGrawD A Scheinberg
Oct 1, 1991·Current Opinion in Immunology·D A Scheinberg
Jul 20, 2001·Hybridoma·K N SyrigosK J Harrington
Oct 24, 2001·Current Opinion in Oncology·E L Sievers, M Linenberger
Jan 31, 2012·Blood·R B WalterIrwin D Bernstein
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A E FrankelJ G Jurcic
Jun 12, 2013·Frontiers in Bioscience (Landmark Edition)·Andrew J CowanR B Walter
Feb 28, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Leslie MortlandJatinder K Lamba
Jun 1, 1997·Leukemia & Lymphoma·P Lefterova, I G Schmidt-Wolf
Apr 24, 2002·Clinical Lymphoma·Irwin D Bernstein
Apr 10, 1999·Annals of Diagnostic Pathology·P G ChuL M Weiss
Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L CamposD Guyotat
Oct 26, 2001·Hematology/oncology Clinics of North America·J P Perentesis, E L Sievers
May 18, 2001·Best Practice & Research. Clinical Haematology·G F TorelliR Foà
Jul 21, 2004·Cancer Genetics and Cytogenetics·Lin ChenHervé Tilly
Jul 1, 1995·British Journal of Haematology·I G Schmidt-WolfS Serke
Jun 14, 2017·Leukemia·C D GodwinR B Walter
Jan 13, 2001·Cancer Biotherapy & Radiopharmaceuticals·A E FrankelD A Scheinberg
Jan 1, 1991·Annals of the New York Academy of Sciences·A NajmanM Guigon
Sep 30, 2020·Expert Opinion on Biological Therapy·Benjamin H GoldensonE D Ball
Sep 28, 2001·Hematological Oncology·M Macheta, J A Yin
Jan 1, 1990·Leukemia & Lymphoma·J W Singer, P J Fialkow
Oct 13, 2017·Blood·Frederick R Appelbaum, Irwin D Bernstein

Related Concepts

LIF protein, human
Monoclonal Antibodies
Colony-Forming Units Assay
Glucosephosphate Dehydrogenase
Growth Inhibitors
Genetic Carriers
Colony-forming Unit
Acute Myeloid Leukemia, M1

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.